GNH USA

Europe — EMA

Minims (Cyclopentolate Hydrochloride)

GNH USA supplies Minims (Cyclopentolate), a mydriatic/cycloplegic anticholinergic for diagnostic eye examinations and pediatric assessments.

Request sourcing

1
Pack/s

What is Cyclopentolate Hydrochloride?

Cyclopentolate, the active ingredient in Minims, is an anticholinergic (muscarinic antagonist) presented as a topical ophthalmic solution for ocular use. It is employed to produce pupil dilation and temporary paralysis of the ciliary muscle during eye examinations, particularly in adults and children.

GNH USA supplies Minims as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Cyclopentolate Hydrochloride used for?

Cyclopentolate is used in ophthalmology to facilitate examination of the anterior segment of the eye. - Diagnostic eye examinations: induces mydriasis to allow clear view of intra‑ocular structures. - Pediatric ophthalmic assessments: provides cycloplegia to temporarily suspend accommodation for accurate refraction. - Pre‑operative ocular evaluation: creates a stable, dilated pupil for surgical planning.

What are the side effects of Cyclopentolate Hydrochloride?

Cyclopentolate may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient stinging or burning sensation upon instillation. - Mild conjunctival hyperemia (redness). - Temporary blurred vision due to pupil dilation. - Light sensitivity (photophobia). - Slight increase in intra‑ocular pressure in susceptible individuals.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Persistent mydriasis lasting several days. - Systemic anticholinergic effects such as dry mouth, tachycardia, or confusion, especially in the elderly. - Allergic contact dermatitis of the eyelid skin. - Severe ocular pain or corneal ulceration.

What precautions apply to Cyclopentolate Hydrochloride?

Before using Cyclopentolate, consider the following safety measures. - Contraindication: Avoid in patients with known hypersensitivity to cyclopentolate or other anticholinergics. - Caution: Use carefully in individuals with narrow-angle glaucoma or a history of intra‑ocular pressure spikes. - Pregnancy: Discuss potential risks with a healthcare professional; use only if clearly needed. - Breastfeeding: Evaluate benefits versus risks; cyclopentolate may be excreted in milk. - Pediatric use: Dose and frequency should be determined by an ophthalmologist experienced in pediatric care. - Store at ambient temperature: keep in the original container, protect from light and moisture.

What does Cyclopentolate Hydrochloride interact with?

Cyclopentolate can interact with other medications that affect cholinergic pathways or intra‑ocular pressure.

Major Interactions (Avoid): - Other potent anticholinergic agents (e.g., atropine) – may increase systemic anticholinergic load. - Drugs that raise intra‑ocular pressure (e.g., corticosteroid eye drops) – risk of acute glaucoma.

Moderate Interactions (Monitor Closely): - Systemic antihistamines or tricyclic antidepressants – may potentiate anticholinergic side effects. - Beta‑blocker eye drops – may mask cycloplegic effect on pupil size. - Topical anesthetics – may enhance ocular irritation when used together.

Frequently asked questions

What is Minims (Cyclopentolate) used for?+
Minims contains cyclopentolate, an anticholinergic eye drop used to dilate the pupil (mydriasis) and temporarily paralyze the ciliary muscle (cycloplegia). These effects facilitate detailed diagnostic examinations of the eye and enable accurate refraction measurements in children.
How does cyclopentolate work in the eye?+
Cyclopentolate blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary muscles. This inhibition relaxes the sphincter muscle, causing the pupil to widen, and relaxes the ciliary muscle, preventing accommodation, which together provide a clear view of intra‑ocular structures.
What is the usual dose of Minims?+
The specific dose and frequency of Minims are determined by the prescribing ophthalmologist based on the patient’s age, condition, and examination requirements. Only a qualified healthcare professional should set the dosing regimen.
Is cyclopentolate safe during pregnancy or breastfeeding?+
Safety data are limited. Cyclopentolate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It may be excreted in breast milk, so a healthcare provider should evaluate the risk‑benefit ratio for nursing mothers.
How do I order Minims from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.
How does cyclopentolate compare with other mydriatic agents?+
Cyclopentolate provides both mydriasis and cycloplegia, unlike agents such as tropicamide, which mainly dilate the pupil with shorter duration. Atropine offers longer‑lasting effects but may have a higher risk of systemic anticholinergic side effects. Choice depends on the required duration and clinical context.
What are the storage and handling requirements for Minims?+
Minims should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the bottle from direct light and moisture to maintain stability. Do not freeze the product.
How is Minims administered?+
Minims is applied topically to the conjunctival sac of the eye. The prescriber will instruct the number of drops and the interval between applications, typically one drop per eye, with the eye gently closed for a brief period to enhance absorption.
What are the most serious risks associated with cyclopentolate?+
The most serious risks include acute angle‑closure glaucoma, prolonged mydriasis, and systemic anticholinergic toxicity such as severe dry mouth, tachycardia, confusion, or delirium, especially in elderly patients or those with pre‑existing conditions.
Who should not use Minims (Cyclopentolate)?+
Minims should be avoided in patients with known hypersensitivity to cyclopentolate or other anticholinergics, those with narrow‑angle or uncontrolled glaucoma, and individuals who have experienced severe systemic anticholinergic reactions. A healthcare professional must assess suitability before use.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Cyclopentolate Hydrochloride
Route
Ocular Use
Manufacturer
Bausch + Lomb Ireland Limited
Origin
EU

Related products